Latest Breaking News On - Moleculin biotech inc - Page 33 : vimarsana.com

Moleculin to Report Full Year 2022 Financial Results on March 22, 2023 and Host Conference Call and Webcast

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,.

United statesJohn paul waymackJonathan fosterJenene thomasWalter klempMoleculin biotech incPrnewswire moleculin biotech incChief executive officerSenior chief medical officerMoleculin biotech conferenceMoleculin biotechTranscription modulator

Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including.

United statesJenene thomasSilicon valley bankMoleculin biotech incDeposit insurance corpMoleculin biotechFederal deposit insuranceTranscription modulator

Moleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including.

United statesJonathanp fosterJenene thomasMoleculin biotech incPrnewswire moleculin biotech incChief financial officerAnnual healthcare conferenceMoleculin biotechTranscription modulator

Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGill shephardWalter klempLiposomal annamycinMoleculin biotech incCompany phaseDrug administrationTeam llcjenene thomasExchange commissionSecurities exchangePrnewswire moleculin biotech incPartial responseFast track statusOrphan drug designationMoleculin biotechTranscription modulator

Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug.

United statesJenene thomasWalter klempMoleculin biotech incDrug administrationExchange commissionSecurities exchangeMoleculin biotechMoleculin chairmanPartial responseFast track statusOrphan drug designationTranscription modulatorSecurities actSecurities exchange actPrivate securities litigation reform act